NICM
KYNB

Neo Ivy Capital Management’s Kyntra Bio KYNB Stock Holding History

Neo Ivy Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-157
Closed -$105K – 523
2021
Q2 		$105K Buy
157
+147
+1,470% +$84.7K 0.11% 252
2021
Q1 		$9K Sell
10
-239
-96% -$254K 0.01% 424
2020
Q4 		$231K Buy
249
+86
+53% +$90.4K 0.26% 137
2020
Q3 		$167K Buy
+163
New +$175K 0.17% 220
2020
Q1 		– Sell
-28
Closed -$30K – 485
2019
Q4 		$30K Buy
+28
New +$28.6K 0.03% 209
2019
Q3 		– Sell
-1,022
Closed -$1.15M – 322
2019
Q2 		$1.15M Buy
+1,022
New +$1.12M 0.65% 57
2019
Q1 		– Sell
-704
Closed -$815K – 317
2018
Q4 		$815K Buy
+704
New +$791K 0.64% 50

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neo Ivy Capital Management's KYNB Position: Q3 2021 in Review

Neo Ivy Capital Management sold out of Kyntra Bio (KYNB) in Q3 2021, closing a stake of 157 shares — an estimated $105K sold.

Neo Ivy Capital Management first reported a position in KYNB in Q4 2018 and held it in 7 quarters. The position peaked at $1.15M in Q2 2019. 164 funds tracked by Wall St. Rank hold KYNB as of Q3 2021.

  • Neo Ivy Capital Management reported no remaining Kyntra Bio position as of Q3 2021 after selling out during the quarter.
  • Neo Ivy Capital Management sold 157 Kyntra Bio shares in Q3 2021, an estimated $105K.
  • Neo Ivy Capital Management first reported a position in Kyntra Bio in Q4 2018 and held it in 7 quarters.
  • Neo Ivy Capital Management's Kyntra Bio position peaked at $1.15M in Q2 2019.
  • 164 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2021.

Based on Neo Ivy Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.